Schrödinger, Inc. (NASDAQ:SDGR) is among the Best Pharmaceutical Stocks.

On May 14, Morgan Stanley lowered its price target on Schrödinger, Inc. (NASDAQ:SDGR) to $17 from $19. The firm maintained an “Equal Weight” rating on the shares.

Separately, Schrödinger, Inc. (NASDAQ:SDGR) maintained full-year guidance for ACV of $218 million to $228 million. The corporation expects 10% to 15% growth over 2025, while projecting drug discovery revenue of $55 million to $65 million and operating expenses below 2025 levels.

The company guided second quarter 2026 ACV at $19 million to $23 million as compared to $23.3 million in the prior-year period, which included $5.0 million of contribution ACV.

Universal Health Services (UHS): Cheap NYSE Stocks to Buy According to Analysts

Separately, the corporation also announced plans for an early access release of its artificial intelligence co-scientist “Bunsen” this summer. The firm described it as an agentic system that autonomously executes molecular discovery workflows and is already used internally throughout research programs.

Schrödinger, Inc. (NASDAQ:SDGR) works in the provision of chemical simulation software solutions to the pharmaceutical industry. It functions through the Software and Drug Discovery business segments.

While we acknowledge the risk and potential of SDGR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SDGR and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1